ILUSTRASI. More than half of the 1,4 billion China population have so far received a non-mRNA booster shot. REUTERS/Aly Song
Sumber: Reuters | Editor: Anastasia Lilin Yuliantina
KONTAN.CO.ID - BEIJING. A Covid-19 vaccine candidate from China's Walvax Biotechnology using mRNA technology triggered a stronger antibody response against the Omicron variant of the coronavirus as a booster dose than Sinovac's shot. Clinical trial data showed.
The result for Walvax's ARCoV candidate, which is yet to be peer reviewed, comes as competition for the Covid booster market intensifies in China, where more than half of the 1,4 billion population have so far received a non-mRNA booster shot.
Hanya Rp 5.000 untuk membaca artikel ini.
BELI SEKARANG
